drugset / Trial / NCT00780676
Personalized Treatment Selection for Metastatic Breast Cancer
Phase 2
Terminated
97 enrolled
M.D. Anderson Cancer Center
AstraZeneca · collabBristol-Myers Squibb · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if researchers can use genetic tests to predict who may benefit from treatment with SprycelTM (dasatinib) or selumetinib (AZD6244).
Timeline
- Start
- 2009-06
- Primary completion
- 2014-05
- Completion
- 2014-05
Outcome
Outcome not reported
Stopped: “Closed early for futility.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selumetinib | Small molecule | 75 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |